Shots:
- Celltrion has reported post-hoc analysis of the P-III (LIBERTY-CD) study of Zymfentra (infliximab-dyyb; SC) vs PBO in pts with mod. to sev. Crohn’s disease, which has been published in the Clinical Gastroenterology and Hepatology
- Among 329 pts, 52.6% had colon-dominant (n=173) & 47.4% ileum-dominant CD (n=105); at Wk. 54, infliximab SC showed superior efficacy to PBO across all EPs, with clinical remission rates of 60.95% vs 37.25% in ileum-dominant & 66.95% vs 29.09% in colon-dominant, regardless of disease location
- Clinical rates were 62.86% vs 41.18% & 67.80% vs 38.18%, while endoscopic rates were 53.33% vs 19.61% & 52.54% vs 18.18% in ileum & colon-dominant pts, respectively, with superior endoscopic responses at Wk. 54 across all ileocolonic segments, incl. terminal ileum, with consistent treatment effect sizes throughout each segment
Ref: PRNewswire | Image: Celltrion | Press Release
Related News: The EC Approves Additional Presentation of Celltrion’s Omlyclo (Biosimilar, Xolair)
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information connect with us at connect@pharmashots.com
